Trial Profile
An Open-Label Randomized Pilot Trial to Evaluate Tolerability, Safety and Applicability of AKITA Inhaled Budesonide Suspension in Children aged 3-11 years with Mild to Moderate Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2013
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SCIPE-001
- 08 Apr 2013 Positive results reported in an Activaero media release.
- 15 Mar 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 24 Jun 2011 New trial record